# A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

> **NCT03964038** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** gilteritinib
- **DRUG:** gilteritinib mini tablet

## Key facts

- **NCT ID:** NCT03964038
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-21
- **Primary completion:** 2019-07-02
- **Final completion:** 2019-07-16
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964038, "A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03964038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*